Micheu MM, Rosca AM. Patient-specific induced pluripotent stem cells as “disease-in-a-dish” models for inherited cardiomyopathies and channelopathies – 15 years of research. World J Stem Cells 2021; 13(4): 281-303 [PMID: 33959219 DOI: 10.4252/wjsc.v13.i4.281]
Corresponding Author of This Article
Miruna Mihaela Micheu, MD, PhD, Doctor, Department of Cardiology, Clinical Emergency Hospital of Bucharest, Floreasca Street 8, Bucharest 014452, Romania. mirunamicheu@yahoo.com
Research Domain of This Article
Cardiac & Cardiovascular Systems
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Stem Cells. Apr 26, 2021; 13(4): 281-303 Published online Apr 26, 2021. doi: 10.4252/wjsc.v13.i4.281
Patient-specific induced pluripotent stem cells as “disease-in-a-dish” models for inherited cardiomyopathies and channelopathies – 15 years of research
Miruna Mihaela Micheu, Ana-Maria Rosca
Miruna Mihaela Micheu, Department of Cardiology, Clinical Emergency Hospital of Bucharest, Bucharest 014452, Romania
Ana-Maria Rosca, Cell and Tissue Engineering Laboratory, Institute of Cellular Biology and Pathology "Nicolae Simionescu", Bucharest 050568, Romania
Author contributions: Both authors equally contributed to the conception of the paper, the literature review and analysis, drafting and to critically revising and editing the manuscript.
Conflict-of-interest statement: The authors declare that they have no competing interests.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Miruna Mihaela Micheu, MD, PhD, Doctor, Department of Cardiology, Clinical Emergency Hospital of Bucharest, Floreasca Street 8, Bucharest 014452, Romania. mirunamicheu@yahoo.com
Received: February 1, 2021 Peer-review started: February 1, 2021 First decision: February 28, 2021 Revised: March 11, 2021 Accepted: March 29, 2021 Article in press: March 29, 2021 Published online: April 26, 2021 Processing time: 79 Days and 17.5 Hours
Core Tip
Core Tip: Induced pluripotent stem cell (iPSC) technology holds a great potential for medical research. Patient-specific iPSC-derived cardiomyocytes offer a unique framework for various applications, such as cardiotoxicity screening, drug discovery, disease modeling, and cell therapy. In the particular case of inherited cardiomyopathies and channelopathies, iPSC-based models have prompted study of disease mechanisms in an individual-/allele-specific manner, as well as the customization of therapeutic regimens. Herein, we present and critically discuss the current knowledge and key experimental approaches that support patient-specific iPSCs as robust “disease-in-a-dish” models for genetic cardiomyopathies and channelopathies after 15 years of research.
